A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Uboldi, Sarah ^a   Calura, Enrica ^b   Beltrame, Luca ^a   Nerini, Ilaria ^a   Marchini, Sergio ^a   Cavalieri, Duccio ^c   Erba, Eugenio ^a   Chiorino, Giovanna ^d   Ostano, Paola ^d   D'Angelo, Daniela ^e   D'Incalci, Maurizio ^a   Romualdi, Chiara ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c Research and Innovation Centre ^*  (Italy)

^d Laboratory of Cancer Genomics   (Italy)

^e CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; MESSENGER RNA; MICRORNA; TRABECTEDIN; 1,3 DIOXOLANE DERIVATIVE; ALKYLATING AGENT; TETRAHYDROISOQUINOLINE DERIVATIVE; TUMOR PROTEIN;

ABL1 GENE; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CCDN1 GENE; CDKN1C GENE; CELL CYCLE REGULATION; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; E2F4 GENE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; IN VITRO STUDY; MYXOSARCOMA; PROMOTER REGION; PROTEIN EXPRESSION; PROTEOMICS; RB1 GENE; SYSTEMS BIOLOGY; TNF GENE; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS; DRUG EFFECT; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; DIOXOLES; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; LIPOSARCOMA, MYXOID; MICRORNAS; NEOPLASM PROTEINS; RNA, MESSENGER; SYSTEMS BIOLOGY; TETRAHYDROISOQUINOLINES; TRANSCRIPTION, GENETIC;

EID: 84859856689     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035423     Document Type: Article

References (48)

1. Krasner CN, McMeekin DS, Chan S, Braly PS, Renshaw FG, et al. (2007) A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br. J. Cancer 97: 1618-1624 doi:10.1038/sj.bjc.6604088.
2. Monk BJ, Sill MW, Hanjani P, Edwards R, Rotmensch J, et al. (2011) Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group. Gynecol. Oncol. 120: 459-463 doi:10.1016/j.ygyno.2010.11.012.
3. Grosso F, Jones RL, Demetri GD, Judson IR, Blay J-Y, et al. (2007) Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 8: 595-602 doi:10.1016/S1470-2045(07)70175-4.
4. Del Campo JM, Roszak A, Bidzinski M, Ciuleanu TE, Hogberg T, et al. (2009) Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann. Oncol. 20: 1794-1802 doi:10.1093/annonc/mdp198.
5. Sessa C, De Braud F, Perotti A, Bauer J, Curigliano G, et al. (2005) Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J. Clin. Oncol. 23: 1867-1874 doi:10.1200/JCO.2005.09.032.
6. Grosso F, Sanfilippo R, Virdis E, Piovesan C, Collini P, et al. (2009) Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann. Oncol. 20: 1439-1444 doi:10.1093/annonc/mdp004.
7. Carter NJ, Keam SJ, (2010) Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer. Drugs 70: 355-376 doi:10.2165/11202860-000000000-00000.
8. D'Incalci M, Galmarini CM, (2010) A review of trabectedin (ET-743): a unique mechanism of action. Mol. Cancer Ther. 9: 2157-2163 doi:10.1158/1535-7163.MCT-10-0263.
9. Hurley LH, Zewail-Foote M, (2001) The antitumor agent ecteinascidin 743: characterization of its covalent DNA adducts and chemical stability. Adv. Exp. Med. Biol. 500: 289-299.
10. Minuzzo M, Marchini S, Broggini M, Faircloth G, D'Incalci M, et al. (2000) Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc. Natl. Acad. Sci. U.S.A. 97: 6780-6784.
11. Minuzzo M, Ceribelli M, Pitarque-Martì M, Borrelli S, Erba E, et al. (2005) Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters. Mol. Pharmacol. 68: 1496-1503 doi:10.1124/mol.105.013615.
12. Grosso F, Jones RL, Demetri GD, Judson IR, Blay J-Y, et al. (2007) Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 8: 595-602 doi:10.1016/S1470-2045(07)70175-4.
13. Forni C, Minuzzo M, Virdis E, Tamborini E, Simone M, et al. (2009) Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol. Cancer Ther. 8: 449-457 doi:10.1158/1535-7163.MCT-08-0848.
14. Uboldi S, Bernasconi S, Romano M, Marchini S, Fuso Nerini I, et al. (2011) Characterization of a new trabectedin resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents. International Journal of Cancer. Journal International Du Cancer. Available:http://www.ncbi.nlm.nih.gov/pubmed/21805478.
15. Aman P, Ron D, Mandahl N, Fioretos T, Heim S, et al. (1992) Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11). Genes Chromosomes Cancer 5: 278-285.
16. Marchini S, Marabese M, Marrazzo E, Mariani P, Cattaneo D, et al. (2008) DeltaNp63 expression is associated with poor survival in ovarian cancer. Ann. Oncol. 19: 501-507 doi:10.1093/annonc/mdm519.
17. Bolstad BM, Irizarry RA, Astrand M, Speed TP, (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193.
18. Smyth GK, (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3 doi:10.2202/1544-6115.1027.
19. Reiner A, Yekutieli D, Benjamini Y, (2003) Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 19: 368-375.
20. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 4: P3.
21. Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, et al. (2007) Integration of biological networks and gene expression data using Cytoscape. Nat Protoc 2: 2366-2382 doi:10.1038/nprot.2007.324.
22. Ho Sui SJ, Mortimer JR, Arenillas DJ, Brumm J, Walsh CJ, et al. (2005) oPOSSUM: identification of over-represented transcription factor binding sites in co-expressed genes. Nucleic Acids Res. 33: 3154-3164 doi:10.1093/nar/gki624.
23. Huber W, von Heydebreck A, Sueltmann H, Poustka A, Vingron M, (2003) Parameter estimation for the calibration and variance stabilization of microarray data. Stat Appl Genet Mol Biol 2: Article3 doi:10.2202/1544-6115.1008.
24. Betel D, Koppal A, Agius P, Sander C, Leslie C, (2010) Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol. 11: R90 doi:10.1186/gb-2010-11-8-r90.
25. Sales G, Coppe A, Bisognin A, Biasiolo M, Bortoluzzi S, et al. (2010) MAGIA, a web-based tool for miRNA and Genes Integrated Analysis. Nucleic Acids Res 38: W352-359 doi:10.1093/nar/gkq423.
26. Kanehisa M, Goto S, (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28: 27-30.
27. Nikolsky Y, Ekins S, Nikolskaya T, Bugrim A, (2005) A novel method for generation of signature networks as biomarkers from complex high throughput data. Toxicol. Lett. 158: 20-29 doi:10.1016/j.toxlet.2005.02.004.
28. Alexiou P, Vergoulis T, Gleditzsch M, Prekas G, Dalamagas T, et al. (2010) miRGen 2.0: a database of microRNA genomic information and regulation. Nucleic Acids Res. 38: D137-141 doi:10.1093/nar/gkp888.
29. Friard O, Re A, Taverna D, De Bortoli M, Corá D, (2010) CircuitsDB: a database of mixed microRNA/transcription factor feed-forward regulatory circuits in human and mouse. BMC Bioinformatics 11: 435 doi:10.1186/1471-2105-11-435.
30. Smyth GK, Michaud J, Scott HS, (2005) Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 21: 2067-2075 doi:10.1093/bioinformatics/bti270.
31. Sill M, Schröder C, Hoheisel JD, Benner A, Zucknick M, (2010) Assessment and optimisation of normalisation methods for dual-colour antibody microarrays. BMC Bioinformatics 11: 556 doi:10.1186/1471-2105-11-556.
32. Inui M, Martello G, Piccolo S, (2010) MicroRNA control of signal transduction. Nat. Rev. Mol. Cell Biol. 11: 252-263 doi:10.1038/nrm2868.
33. Osella M, Bosia C, Corá D, Caselle M, (2011) The role of incoherent microRNA-mediated feedforward loops in noise buffering. PLoS Comput. Biol. 7: e1001101 doi:10.1371/journal.pcbi.1001101.
34. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57-70.
35. Witkiewicz-Kucharczyk A, Bal W, (2006) Damage of zinc fingers in DNA repair proteins, a novel molecular mechanism in carcinogenesis. Toxicol. Lett. 162: 29-42 doi:10.1016/j.toxlet.2005.10.018.
36. Duan Z, Choy E, Harmon D, Yang C, Ryu K, et al. (2009) ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines. PLoS ONE 4: e6967 doi:10.1371/journal.pone.0006967.
37. Imoto I, Yang ZQ, Pimkhaokham A, Tsuda H, Shimada Y, et al. (2001) Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res. 61: 6629-6634.
38. Blower PE, Verducci JS, Lin S, Zhou J, Chung J-H, et al. (2007) MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol. Cancer Ther. 6: 1483-1491 doi:10.1158/1535-7163.MCT-07-0009.
39. Giovannetti E, Erozenci A, Smit J, Danesi R, Peters GJ, (2011) Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Critical Reviews in Oncology/Hematology. Available: http://www.ncbi.nlm.nih.gov/pubmed/21546262. Consultato 8 Set 2011.
40. Shi L, Chen J, Yang J, Pan T, Zhang S, et al. (2010) MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res. 1352: 255-264 doi:10.1016/j.brainres.2010.07.009.
41. Li Y, Zhu X, Gu J, Hu H, Dong D, et al. (2010) Anti-miR-21 oligonucleotide enhances chemosensitivity of leukemic HL60 cells to arabinosylcytosine by inducing apoptosis. Hematology 15: 215-221 doi:10.1179/102453310X12647083620840.
42. Gu J, Zhu X, Li Y, Dong D, Yao J, et al. (2011) miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines. Med. Oncol. 28: 211-218 doi:10.1007/s12032-009-9413-7.
43. Sorrentino A, Liu C-G, Addario A, Peschle C, Scambia G, et al. (2008) Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol. Oncol. 111: 478-486 doi:10.1016/j.ygyno.2008.08.017.
44. Hebert C, Norris K, Scheper MA, Nikitakis N, Sauk JJ, (2007) High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol. Cancer 6: 5 doi:10.1186/1476-4598-6-5.
45. Boni V, Bitarte N, Cristobal I, Zarate R, Rodriguez J, et al. (2010) miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Mol. Cancer Ther. 9: 2265-2275 doi:10.1158/1535-7163.MCT-10-0061.
46. Conyers R, Young S, Thomas DM, (2011) Liposarcoma: molecular genetics and therapeutics. Sarcoma 2011 483154 doi:10.1155/2011/483154.
47. Kastan MB, Bartek J, (2004) Cell-cycle checkpoints and cancer. Nature 432: 316-323 doi:10.1038/nature03097.
48. Alao JP, (2007) The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol. Cancer 6: 24 doi:10.1186/1476-4598-6-24.